Celltrion

Celltrion, a pharmaceutical preparation manufacturing company headquartered in South Korea, has reported its greenhouse gas (GHG) emissions for recent years, demonstrating a commitment to climate action.

For 2024, Celltrion's total GHG emissions were approximately 121.6 million kg CO2e. This figure comprises Scope 1 emissions totalling about 27.1 million kg CO2e, Scope 2 emissions of approximately 52.0 million kg CO2e, and Scope 3 emissions amounting to about 42.4 million kg CO2e. Key contributors to its Scope 3 emissions include downstream transportation and distribution (around 26.9 million kg CO2e) and upstream transportation and distribution (approximately 18.1 million kg CO2e).

In 2023, the company's total emissions were approximately 93.6 million kg CO2e. This included Scope 1 emissions of roughly 22.5 million kg CO2e, Scope 2 emissions of about 42.3 million kg CO2e, and Scope 3 emissions totalling approximately 28.8 million kg CO2e.

Celltrion has established ambitious reduction targets. The company aims to achieve carbon neutrality by 2050. More immediately, it has set a goal to reduce GHG emissions by 50% by 2030, using 2020 as a baseline. Furthermore, Celltrion announced a Net Zero commitment for its domestic operations, targeting a reduction of Scope 1 and 2 emissions by 42% by 2030 and 100% by 2045 from a 2022 base year. While Scope 3 emissions data for 2022 and 2021 were not fully disclosed, Celltrion did report Scope 1 emissions of approximately 21.2 million kg CO2e and Scope 2 emissions of about 35.3 million kg CO2e for 2022, and Scope 1 emissions of approximately 19.4 million kg CO2e and Scope 2 emissions of about 35.2 million kg CO2e for 2021. For 2020, Scope 1 emissions were reported as approximately 18.3 million kg CO2e and Scope 2 as about 34.3 million kg CO2e. Previous years, including 2019, also show Scope 1 and Scope 2 emissions without comprehensive Scope 3 data.